

Detection of *EML4-ALK* fusion gene and features associated with *EGFR* mutations in Chinese patients with non-small-cell lung cancer

Miaomiao Wen
Xuejiao Wang
Ying Sun
Jinghua Xia
Liangbo Fan
Hao Xing
Zhipei Zhang
Xiaofei Li

Department of Thoracic Surgery,
Tangdu Hospital, The Fourth Military
Medical University, Xi'an, Shaanxi,
People's Republic of China

Purpose: Echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (*EML4-ALK*) and *epidermal growth factor receptor* (*EGFR*) define specific molecular subsets of lung cancer with distinct clinical features. We aimed at revealing the clinical features of *EML4-ALK* fusion gene and *EGFR* mutation in non-small-cell lung cancer (NSCLC).

Methods: We enrolled 694 Chinese patients with NSCLC for analysis. *EML4-ALK* fusion gene was analyzed by real-time polymerase chain reaction, and *EGFR* mutations were analyzed by amplified refractory mutation system.

Results: Among the 694 patients, 60 (8.65%) patients had *EML4-ALK* fusions. In continuity correction χ^2 test analysis, *EML4-ALK* fusion gene was correlated with sex, age, smoking status, and histology, but no significant association was observed between *EML4-ALK* fusion gene and clinical stage. A total of 147 (21.18%) patients had *EGFR* mutations. In concordance with previous reports, *EGFR* mutation was correlated with age, smoking status, histology, and clinical stage, whereas patient age was not significantly associated with *EGFR* mutation. Meanwhile, to our surprise, six (0.86%) patients had coexisting *EML4-ALK* fusions and *EGFR* mutations.

Conclusion: *EML4-ALK* fusion gene defines a new molecular subset in patients with NSCLC. Six patients who harbored both *EML4-ALK* fusion genes and *EGFR* mutations were identified in our study. The *EGFR* mutations and the *EML4-ALK* fusion genes are coexistent.

Keywords: NSCLC, *EML4-ALK* fusion gene, *EGFR* mutation, RT-PCR

Introduction

Lung cancer is one of the most common malignancies and is a leading cause of cancer-related deaths worldwide, and it is associated with a 5-year survival rate of less than 15%.^{1,2} Non-small-cell lung cancer (NSCLC) accounts for approximately 80%–85% of lung cancer. Although progress has been made in traditional surgery, chemotherapy, and radiotherapy for the treatment of advanced lung cancer, clinical outcomes are still considered unsatisfactory, and the median survival rates are still limited.³ In recent years, with the development of molecular biology and human genomics, people are paying growing attention to tumor pathogenesis; molecular targeted therapy with high specificity and little adverse reactions has become an important therapeutic modality for lung cancer;⁴ and people have achieved great success, especially in treating patients with NSCLC. A successful example is the identification of the *epidermal growth factor receptor* (*EGFR*) mutation as a reliable, predictive biomarker for *EGFR* tyrosine kinase inhibitors (TKIs) treatment. In patients carrying the *EGFR* mutation who have been previously untreated, *EGFR*-TKIs have been demonstrated to be superior to cytotoxic chemotherapy.⁵

Correspondence: Zhipei Zhang; Xiaofei Li
Department of Thoracic Surgery, Tangdu
Hospital, The Fourth Military Medical
University, 1 Xinsi Road, Xi'an, 710038,
Shaanxi, People's Republic of China
Tel +86 29 8477 7934
Email zpzpyy@fmmu.edu.cn;
l_tdxw@163.com

A fusion protein between the *echinoderm microtubule-associated protein-like 4 (EML4)* and the *anaplastic lymphoma kinase (ALK)* in NSCLC was first identified by Soda in 2007.⁶ *EML4-ALK* is a fusion gene, which represents a new molecular target. It has been reported that the incidence of *ALK* rearrangement ranged from approximately 3% to 13% in unselected or selected patients with NSCLC.^{7–10} The *EML4-ALK* translocation can result in constitutive *ALK* kinase activity and represents an oncogenic addiction pathway in lung cancer. *EML4-ALK* possesses potent oncogenic activity both in vitro and in vivo, and the tumor can quickly fade after administration of ALK-TKIs.^{6,11} Crizotinib, a small-molecule ALK-TKI, showed significant benefit to patients with advanced NSCLC with *EML4-ALK* fusion in clinical trials and has been approved by the US Food and Drug Administration for these patients.¹²

The present study focuses on the relationship between *EML4-ALK* fusion and *EGFR* mutation. Previous studies proved that *EML4-ALK* fusion gene and *EGFR* mutation have largely been reported to be mutually exclusive.^{7,13,14} During the detection of *EML4-ALK*, patients with coexisting *EML4-ALK* fusion gene and *EGFR* mutation have been reported in some clinical cases.^{15–17} Therefore, we should pay close attention to the coexisting type rates that occurred in our study. In this study, we analyzed the relationship between *EML4-ALK* fusion gene and *EGFR* mutation. Meanwhile, we investigated the prevalence of two major mutations and their clinical characteristics in 694 unselected Chinese patients with NSCLC. These results can provide theoretical basis and important reference for individualized treatment in NSCLC.

Materials and methods

Patients

Fresh tumor specimens were obtained from 694 consecutive Chinese patients with NSCLC who underwent surgery at the Department of Thoracic Surgery, Tangdu Hospital (Xi'an, Shaanxi, People's Republic of China) from March 2012 to September 2014. The study was approved by the Review Board of the Fourth Military Medical University. Written informed consent was obtained from each patient prior to testing.

Clinical characteristics

Medical records of all patients including age, sex, smoking status, histology, and clinical stage were acquired. All patients suffered from NSCLC for the first time, and none of them had received any neoadjuvant chemotherapy or radiotherapy before surgery. Tumor histology was classified according to the 3rd World Health Organization (WHO)/International

Association for the Study of Lung Cancer (IASLC) criteria.¹⁸ Tumor stages were determined using Version 7 of the IASLC (IASLC, Aurora, CO, USA). The histological subtypes of all patients were reassessed by at least two lung pathologists.

EGFR mutation and *EML4-ALK* fusion gene analysis

EGFR mutation detection: Genomic DNA was isolated and purified from fresh tumor specimens using TIANamp Genomic DNA Kit (Taingen Biotech, Beijing, People's Republic of China) according to the manufacturer's instructions. After that, *EGFR* mutations were analyzed using the principle of amplified refractory mutation system (ARMS),¹⁹ following the protocol of the AmoyDx *EGFR* Gene Mutation Detection Kit (Amoy Diagnostics, Haicang, Xiamen, People's Republic of China) and covering 29 *EGFR* mutation hotspots from exons 18 to 21. The assay was carried out according to the manufacturer's instructions using the MX3005P (Stratagene, La Jolla, CA, USA) real-time polymerase chain reaction (RT-PCR) system. PCR was performed with initial denaturation at 95°C for 5 minutes, followed by 15 cycles of amplification (at 95°C for 25 s, 64°C for 20 s, and 72°C for 20 s) and a final denaturation followed by 31 cycles of amplification (at 93°C for 25 s, 60°C for 35 s, and 72°C for 20 s), and the FAM and HEX signals were collected at 60°C. The results were analyzed according to the criteria defined by the manufacturer's instructions. Positive results were defined as Ct (sample) – Ct (control) < Ct (cut-off).

EML4-ALK fusion gene detection: Total RNAs were extracted from fresh cancer tissues using an E.Z.N.A Total RNA Kit I (OMEGA Bio-tek, Norcross, GA, USA) following the manufacturer's instructions. *EML4-ALK* fusion genes were detected by RT-PCR, following the protocol given in the AmoyDx *EML4-ALK* Fusion Gene Detection Kit (Amoy Diagnostics). The assay was carried out according to the manufacturer's instructions with the MX3005P (Stratagene) RT-PCR system. The PCR conditions consisted of initial denaturation at 95°C for 5 minutes, followed by 15 cycles of amplification (at 95°C for 25 s, 64°C for 20 s, and 72°C for 20 s) and final denaturation followed by 31 cycles of amplification (at 93°C for 25 s, 60°C for 35 s, and 72°C for 20 s), and the FAM signal was collected at 60°C. The results were analyzed according to the criteria defined by the manufacturer's instructions. Positive results were defined as Ct (sample) < 30.

Statistical analyses

Statistical analysis was performed using SPSS Version 16.0 Statistical Software (SPSS Inc., Chicago, IL, USA). The

χ^2 test or Fisher's exact test was used to assess the relationship between the presence of *EGFR* mutation and clinical features as well as *EML4-ALK* fusion gene and the clinical features. All *P*-values were based on a two-sided hypothesis, and the statistical significance was set at $P < 0.05$ for all analyses.

Results

Correlation between *EML4-ALK* fusion gene and clinicopathologic characteristics

The clinical characteristics of these 694 patients are described in Table 1. *EML4-ALK* fusion genes were identified in 60 (8.65%) of all cases. *EML4-ALK* fusion gene was correlated with age, sex, smoking status, and histology, but no significant association was observed between *EML4-ALK* fusion gene and clinical stage.

The proportion of clinicopathologic characteristics in patients with *EML4-ALK* fusion genes

Among the 60 patients with *EML4-ALK* fusion gene, 41 (68.33%) were of lower median age and 19 (31.67%) were of higher median age; 32 (53.33%) were male and 28 (46.67%) were female; 34 (56.67%) were never smokers

and 26 (43.33%) were smokers; 14 (23.34%) patients were in stage I, eight (13.33%) were in stage II, 26 (43.34%) were in stage III, and 12 (20%) were in stage IV; according to the IASLC, 42 (70%) were adenocarcinomas, eight (13.33%) were squamous cell carcinomas, seven (11.67%) were adenosquamous carcinomas, and three (5%) were other specified carcinomas.

Correlation between *EGFR* mutation and clinicopathologic characteristics

As shown in Table 2, of the 694 patients, we identified 147 (21.18%) patients who harbored *EGFR* mutations. Clinical and pathological characteristics were analyzed for association with *EGFR* mutation. Sex, smoking status, histology, and clinical stage were associated with *EGFR* mutation, but no significant association was found between *EGFR* mutation and age.

The proportion of clinicopathologic characteristics in patients with *EGFR* mutations

Of the 147 patients with *EGFR* mutation, 77 (52.38%) were of lower median age and 70 (47.62%) were of higher median age; 64 (43.54%) were male and 83 (56.46%) were

Table 1 Association of *EML4-ALK* fusion gene with clinicopathological characteristics

Characteristics	Total ^a	<i>EML4-ALK</i> fusion ^a	<i>P</i> -value
Total patients	694	60	
Sex			0.000
Male	504 (72.62)	32 (6.35)	
Female	190 (27.38)	28 (14.74)	
Age (years)			0.002
<60	340 (48.99)	41 (12.06)	
≥60	354 (51.01)	19 (5.37)	
Smoking history			0.001
Never	259 (37.32)	34 (13.13)	
Ever ^b	435 (62.68)	26 (5.98)	
Histology			0.000
ADC	315 (45.38)	42 (13.33)	
SCC	255 (36.74)	8 (3.14)	
ADSQ	68 (9.81)	7 (10.29)	
Other NSCLC ^c	56 (8.07)	3 (5.36)	
Clinical stage			0.063
I	208 (29.97)	14 (6.73)	
II	152 (21.90)	8 (5.26)	
III	248 (35.73)	26 (10.48)	
IV	86 (12.39)	12 (13.95)	

Notes: ^aValues in parentheses indicate percentage. ^bA person who smoked more than 100 cigarettes in his/her past history was defined as an ever smoker. ^cOther types included sarcomatoid, large cell, and mucoepidermoid.

Abbreviations: *EML4-ALK*, echinoderm microtubule-associated protein-like 4—anaplastic lymphoma kinase; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ADSQ, adenosquamous carcinoma; NSCLC, non-small-cell lung cancer.

Table 2 Association of *EGFR* mutation with clinicopathological characteristics

Characteristics	Total ^a	<i>EGFR</i> mutation ^a	<i>P</i> -value
Total patients	694	147 (21.18)	
Sex			0.000
Male	504 (72.62)	64 (12.70)	
Female	190 (27.38)	83 (43.68)	
Age (years)			0.355
<60	340 (48.99)	77 (22.65)	
≥60	354 (51.01)	70 (19.77)	
Smoking history			0.000
Never	259 (37.32)	105 (40.54)	
Ever ^b	435 (62.68)	39 (8.97)	
Histology			0.000
ADC	315 (45.38)	114 (36.19)	
SCC	255 (36.74)	11 (4.31)	
ADSQ	68 (9.81)	17 (25)	
Other NSCLC ^c	56 (8.07)	5 (8.93)	
Clinical stage			0.008
I	208 (29.97)	52 (25)	
II	152 (21.90)	17 (11.18)	
III	248 (35.73)	57 (22.98)	
IV	86 (12.39)	21 (24.42)	

Notes: ^aValues in parentheses indicate percentage. ^bA person who smoked more than 100 cigarettes in his/her past history was defined as an ever smoker. ^cOther types included sarcomatoid, large cell, and mucoepidermoid.

Abbreviations: *EGFR*, epidermal growth factor receptor; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ADSQ, adenosquamous carcinoma; NSCLC, non-small-cell lung cancer.

female; 105 (71.43%) were never smokers and 39 (28.57%) were smokers; 52 (35.37%) patients were in stage I, 17 (11.56%) were in stage II, 57 (38.78%) were in stage III, and 21 (14.29%) were in stage IV; according to the IASLC, 114 (77.55%) were adenocarcinomas, eleven (7.48%) were squamous cell carcinomas, 17 (11.56%) were adenosquamous carcinomas, and five (3.41%) were other specified carcinomas; in addition, three cases exhibited double mutations in *EGFR* exons, including E(G719X; L861Q), E(G719X; S768I), and E(I9-del; T790M).

Characteristics in patients with NSCLC with *EGFR*/*EML4-ALK* coalterations

Six patients (0.86%) had coexistence of *EGFR* mutation and *EML4-ALK* fusion gene. Among the patients with coalterations, three (50%) had adenocarcinomas, one (16.7%) had mucoepidermoid carcinoma, and two (33.3%) had sarcomatoid carcinomas; four (66.7%) were male and two (33.3%) were female; four (66.7%) had a lower median age and two (33.3%) had a higher median age; all the six (100%) patients were never smokers; two (33.3%) patients were in stage I, one (16.7%) was in stage II, two (33.3%) were in stage III, and one (16.7%) was in stage IV. The clinical characteristics of the patients with coalterations are shown in Table 3. Typical results of patients with coalterations are shown in Figure 1.

Discussion

With the development of molecular medicine, the application of several molecular targeting drugs in lung cancer has garnered increased attention, and remarkable successes have been reported in several patients with NSCLC. Targeted biological therapies have led patients with advanced NSCLC to new therapeutic options. At present, *EGFR*-TKIs, such as gefitinib and erlotinib, have shown great efficacy in patients with NSCLC who have activation mutations in the *EGFR* gene.^{20,21} Recently, the discovery of the *EML4-ALK* fusion gene, which was first reported in NSCLC in 2007, represents a new molecular target. *EML4-ALK* fusion has been reported to suppress the growth of *EML4-ALK*-fusion-gene-positive

cells.^{15,22} Thus, the *ALK* inhibitors can be effective for patients with NSCLC whose tumors contain an *EML4-ALK* fusion gene. There are three usual methods for genetic detection – fluorescence in situ hybridization (FISH), RT-PCR, and immunohistochemistry.^{23–25} We choose different methods according to different specimen types. RT-PCR is a highly sensitive and specific technique, and since fresh tumor samples after lung resection could be used in our study; we adopted RT-PCR as a detection method.

Previous studies reported that the incidence of *EML4-ALK* fusion gene varied from 3% to 5% in unselected populations, but the frequency is up to 13.5% in selected populations.^{16,26} The incidence of *EML4-ALK* fusion gene in Chinese patients with NSCLC was approximately 2.6%–11.9%, but the studies had some limitations, including smaller sample size. In our study, *EML4-ALK* fusion gene in unselected patients was detected by RT-PCR, and the incidence of *EML4-ALK* fusion gene was 8.65% (60/694). The clinical characteristics of *ALK*-positive or -negative patients were analyzed by χ^2 testing, which showed significant differences in sex, age, smoking status, and histology. The proportion of *EML4-ALK*-positive patients seemed to be of younger age, light or never smokers, and had histology of adenocarcinomas. There are greater differences between the sexes in the patients who harbored *EML4-ALK* fusion gene. Shaw et al⁹ found that *EML4-ALK* fusion gene occurred more frequently in men, those of relatively young age, nonsmokers, and those with adenocarcinomas.⁹ However, in our study, the incidence of *EML4-ALK* fusion gene was significantly higher in women than in men. We suggest that the patients with NSCLC, both men and women, should be tested for *EML4-ALK* fusion gene.

EGFR mutation rate has obvious regional differences in NSCLC; it is reported that the *EGFR*-positive rate was found to be 30% in Asian patients²⁷ but only 15% in American patients,²⁸ and *EGFR* mutation was detected predominantly in Asian people, females, light or never smokers, and adenocarcinomas, which was consistent with previous reports.^{5,29} At present, the relationship between *EGFR* mutation and age is scarce; there is no clear explanation, and the mechanism still needs to be

Table 3 The clinical characteristics of six patients with *EML4-ALK* fusions and *EGFR* mutations

Patient ID	<i>EGFR</i> mutation	<i>ALK</i> fusion	Sex	Age (years)	Smoking status	Tumor histology	Stage
1	E(I9-del)	Positive	Male	46	Never	Adenocarcinoma	IIA
2	E(L858R)	Positive	Male	24	Never	Mucoepidermoid carcinoma	IB
3	E(I9-del)	Positive	Female	64	Never	Adenocarcinoma	IB
4	E(L861Q)	Positive	Male	67	Never	Sarcomatoid carcinoma	IV
5	E(G719X)	Positive	Female	47	Never	Adenocarcinoma	IIIB
6	E(I9-del)	Positive	Male	38	Never	Sarcomatoid carcinoma	IIIA

Abbreviations: *EML4-ALK*, echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase; *EGFR*, epidermal growth factor receptor.




Figure 1 Representative results of patients with coalterations.

Notes: Amplification plots demonstrate the typical results of *EGFR* mutation and *EML4-ALK* fusion of patient 1 (A and B), patient 2 (C and D), and patient 3 (E and F). A, C, and E demonstrate the results of exon 19 deletion mutation, exon 21 L858R point mutation, and exon 18 G719X point mutation, respectively. B, D, and F demonstrate the results of *EML4-ALK* fusion, respectively.

Abbreviations: *EGFR*, epidermal growth factor receptor; *EML4-ALK*, echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase.

studied further. In this study, there was no statistical significance between *EGFR* mutation and age.

EGFR mutation and *EML4-ALK* fusion have some similar clinical features, for example, these patients are light or never smokers and had histology of adenocarcinomas. Although previous reports have indicated that *EML4-ALK* fusion gene

and *EGFR* mutation were considered to be mutually exclusive in general,^{9,14,15,30} several studies have reported the coexistence of the *EGFR* mutation and *EML4-ALK* fusion gene, and the clinical features including Asian ethnicity, female, never or light smoking, adenocarcinomas, young patients with advanced cancer, and harboring *EGFR* mutations in

exon 19 or exon 21.^{15,31,32} In the present study, six patients had coexisting *EML4-ALK* fusion genes and *EGFR* mutations; further analysis revealed that of these six patients, four were male, three had adenocarcinomas, four were in relatively early stage of disease, four were of younger age, and *EGFR* mutations were either exon 19 deletion mutations (3/6), or exon 21 point mutations (2/6), or exon 18 point mutation (1/6). In general, patients need to be tested for the presence of *EML4-ALK* fusion gene when the *EGFR* mutation is negative. Given the existence of double mutation, we can detect both *EML4-ALK* fusion and *EGFR* mutation to prevent missing *EML4-ALK* fusion gene, and hence provide more choices to patients. *EGFR*-TKIs have become an indispensable and important modality for treating advanced NSCLC with an *EGFR* mutation. A series of driver genes of lung cancer have been identified, and *EML4-ALK* fusion gene has become one of the research hotspots in recent years. However, because only few cases of coexistence of *EGFR* mutation and *EML4-ALK* fusion gene have been reported to date, and further research needs to be done. It still remains unclear as to how to introduce TKIs to patients who have coexisting *EML4-ALK* fusion gene and *EGFR* mutation. The appropriate treatment for coalternative patients should be further identified in the clinical trials.

Conclusion

We investigated the frequency of *EML4-ALK* fusion gene and its association with clinicopathologic factors in 694 patients with NSCLC with identified *EGFR* mutation. Meanwhile, we found six patients had coexisting *EML4-ALK* fusion genes and *EGFR* mutations. The role of *EML4-ALK* fusion gene as an oncogenic driver may be more important in NSCLC than what we expected. Furthermore, our study also revealed a strong association between *EML4-ALK* fusion gene and sex, age, smoking status, and histology. Our data also suggested *EML4-ALK* status should be investigated in unexplained cases of TKI-resistance of *EGFR*-mutated NSCLC. To better use targeted drugs, further study focusing on specific subgroups with *EML4-ALK/EGFR* coalterations should be performed in future.

Acknowledgment

The authors thank Ms Ruijuan Zhang, Pfizer Oncology (Beijing, People's Republic of China) for professional comments and references.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69–90.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev*. 2010;19(8):1893–1907.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 2002;346(2):92–98.
4. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. *Cancer Cell*. 2012;21(3):448.e2.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2004;350(21):2129–2139.
6. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature*. 2007;448(7153):561–566.
7. Horn L, Pao W. *EML4-ALK*: honing in on a new target in non-small-cell lung cancer. *J Clin Oncol*. 2009;27(26):4232–4235.
8. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *J Clin Oncol*. 2010;28(30):4616–4620.
9. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor *EML4-ALK*. *J Clin Oncol*. 2009;27(26):4247–4253.
10. Inamura K, Takeuchi K, Togashi Y, et al. *EML4-ALK* fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol*. 2008;3(1):13–17.
11. Soda M, Takada S, Takeuchi K, et al. A mouse model for *EML4-ALK*-positive lung cancer. *Proc Natl Acad Sci U S A*. 2008;105(50):19893–19897.
12. Bergeth K, Shaw AT, Ou SH, et al. *ROS1* rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012;30(8):863–870.
13. Gainor JF, Varghese AM, Ou SH, et al. *ALK* rearrangements are mutually exclusive with mutations in *EGFR* or *KRAS*: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res*. 2013;19(15):4273–4281.
14. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of *EML4-ALK* non-small-cell lung cancer. *Eur J Cancer*. 2010;46(10):1773–1780.
15. Koivunen JP, Mermel C, Zejnullahu K, et al. *EML4-ALK* fusion gene and efficacy of an *ALK* kinase inhibitor in lung cancer. *Clin Cancer Res*. 2008;14(13):4275–4283.
16. Zhang X, Zhang S, Yang X, et al. Fusion of *EML4* and *ALK* is associated with development of lung adenocarcinomas lacking *EGFR* and *KRAS* mutations and is correlated with *ALK* expression. *Mol Cancer*. 2010;9:188.
17. Tiseo M, Gelsomino F, Boggiani D, Zhang J. *EGFR* and *EML4-ALK* gene mutations in NSCLC: a case report of erlotinib resistant patient with both concomitant mutations. *Lung Cancer*. 2011;71(2):241–243.
18. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. *Semin Roentgenol*. 2005;40(2):90–97.
19. Liu J, Zhao R, Zhang J, Zhang J. ARMS for *EGFR* mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens. *J Cancer Res Clin Oncol*. 2015;141(2):221–227.
20. Paez JG, Jänne PA, Lee JC, et al. *EGFR* mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004;304(5676):1497–1500.
21. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947–957.
22. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the *EML4-ALK* transforming gene in non-small cell lung cancer. *Cancer Res*. 2008;68(13):4971–4976.

23. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clin Cancer Res.* 2010;16(5):1561–1571.
24. Boland JM, Erdogan S, Vasmatazis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. *Hum Pathol.* 2009;40(8):1152–1158.
25. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clin Cancer Res.* 2009;15(16):5216–5223.
26. Vasikova A. EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy. *Klin Onkol.* 2012;25(6):434–439.
27. Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. *J Thorac Oncol.* 2007;2(5):430–439.
28. Keedy VL, Temin S, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. *Clin Oncol.* 2011;29(15):2121–2127.
29. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from “never smoker” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A.* 2004;101(36):13306–13311.
30. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol.* 2009;22(4):508–515.
31. Zhang XC, Zhang S, Yang XN, et al. Multiple EML4-ALK fusion transcripts and concurrent EGFR kinase mutation in Chinese non-small cell lung cancer. *J Thorac Oncol.* 2009;4(9):S549.
32. Zeng Z, Wu Y. Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation. *Zhong-guo Fei Ai Za Zhi.* 2011;14(11):880–884. Chinese.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress